Cue Biopharma (CUE) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nkarta (NKTX) has outperformed Cue Biopharma (CUE) over the past year, gaining 6.2% versus a loss of 13.2%. Over five years, NKTX leads with a -87.9% price change compared with -94.1% for CUE. Cue Biopharma is the larger company by market cap ($162.2 million vs $159.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | NKTX |
|---|---|---|
| Share price | $22.33 | $2.22 |
| Market cap | $162.21M | $159.01M |
| 1-day change | -0.80% | -2.20% |
| YTD return | +144.04% | +20.00% |
| 1-year return | -13.25% | +6.22% |
| 5-year return | -94.09% | -87.90% |
| EPS (TTM) | $-29.59 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $3.72 |
| 52-week low | $4.98 | $1.70 |
| Distance from 52-week high | -50.92% | -40.32% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +294.09% | +387.84% |
| Average volume | 267.15K | 613.16K |
| Shares outstanding | 7.26M | 71.62M |
| Employees | 29 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed CUE by 19.5 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
CUE vs NKTX FAQ
Which is bigger, Cue Biopharma or Nkarta?
Cue Biopharma (CUE) is larger, with a market capitalization of $162.21M compared with $159.01M for Nkarta (NKTX).
Which stock has performed better over the past year, CUE or NKTX?
NKTX returned +6.22% over the past 12 months, compared with -13.25% for CUE (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.